Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical company focusing on degenerative retinal diseases, has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. Dr. Nathan Mata, the company's Chief Scientific Officer, will present a corporate update on August 15, 2024, at 7:00 am ET.
The presentation will be available as a webcast under the "Events" tab on Belite Bio's investor relations website. Interested parties can access the replay, which will be archived for 90 days following the presentation date. This event provides an opportunity for Belite Bio to showcase its progress in developing novel therapeutics for unmet medical needs in retinal diseases.
Belite Bio (NASDAQ: BLTE), un'azienda biofarmaceutica in fase clinica che si concentra sulle malattie retiniche degenerative, ha annunciato la sua partecipazione alla 4ª Conferenza Virtuale di Oculistica Annuale H.C. Wainwright. Il Dott. Nathan Mata, Chief Scientific Officer dell'azienda, presenterà un aggiornamento aziendale il 15 agosto 2024, alle 7:00 ET.
La presentazione sarà disponibile come webcast nella sezione
- None.
- None.
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Dr. Nathan Mata, Chief Scientific Officer of Belite Bio, will present a corporate update at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference.
A webcast of the presentation will be available on Thursday, August 15, 2024, at 7:00 am ET under the "Events" tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replay will be archived for 90 days following the presentation date.
About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt Disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on Twitter, Instagram, LinkedIn, and Facebook or visit us at www.belitebio.com.
Media Relations Contact:
Jennifer Wu
ir@belitebio.com
Investor Relations Contact:
Julie Fallon
belite@argotpartners.com
FAQ
When is Belite Bio (BLTE) presenting at the H.C. Wainwright Ophthalmology Conference?
Who will be presenting the corporate update for Belite Bio (BLTE)?
How long will the webcast replay of Belite Bio's (BLTE) presentation be available?
Where can I access the webcast of Belite Bio's (BLTE) presentation?
What is the main focus of Belite Bio's (BLTE) drug development?
